Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2630265 | 0.93 | KDR (0.37) | KIT | |
| SCHEMBL2630262 | 0.91 | KIT (0.36) | KIT | |
| SCHEMBL2630277 | 0.91 | JAK1 (0.39) | KIT | |
| SCHEMBL2630264 | 0.90 | KIT (0.35) | KITCHEK1CHEK2 | |
| SCHEMBL2630429 | 0.86 | CDK9 (0.43) | CHEK1CHEK2 | |
| SCHEMBL2630238 | 0.86 | JAK2 (0.42) | — | |
| SCHEMBL2630255 | 0.83 | — | — | |
| SCHEMBL2630326 | 0.83 | — | — | |
| SCHEMBL2630293 | 0.82 | — | — | |
| SCHEMBL2630187 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008359-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-14 | — | — | US | disclosed |
| US-20160008359-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-14 | — | — | US | disclosed |
| US-9120790-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120790-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140336171-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-11-13 | — | — | US | disclosed |
| US-8822681-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822681-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | US | disclosed |
| US-8450489-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767816-B2 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767816-B2 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2007084557-A2 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008359-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KIT 940/4885CHEK1 314/4885CHEK2 167/4885 |
| US-20140336171-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KIT 940/4885CHEK1 314/4885CHEK2 167/4885 |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | JAK1, JAK3, MYLK2 | KIT 2041/4885CHEK1 513/4885CHEK2 677/4885 |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KIT 940/4885CHEK1 314/4885CHEK2 167/4885 |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KIT 940/4885CHEK1 314/4885CHEK2 167/4885 |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | JAK3, JAK1, JAK2 | KIT 940/4885CHEK1 314/4885CHEK2 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.